Dr. Barry Dworkin

Bowel cancer treatment strategy developed using molecular oncology

Madely Health Headlines Commentary for July 21, 2014

[display_podcast]

Source:

Bowel cancer breakthrough may benefit thousands of patients

Reference:

ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. Cell Reports, 2014; 7 (6): 1940 DOI:10.1016/j.celrep.2014.05.032

Related posts:

  1. Ottawa Hospital creates new Medical Oncology lab leading to development of pharmacogenomic medicine for the region
  2. Genes research offers cancer treatment hope
  3. New biotherapeutic cancer treatment centre an excellent addition to novel therapeutic solutions
  4. New insights into how prostate cancer protects itself from latest therapies after researchers uncover the gene responsible for this resistance while investigating new drug that circumvents these protective mechanisms.